A Johns Hopkins University team has clinical proof-of-concept data for slowing the progression of Alzheimer's disease by reducing activity in the hippocampus with antiepileptic drugs. AgeneBio has licensed the IP and is planning a Phase II trial of an antiepileptic to prevent AD.